Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals has secured £570,000 through the issuance of new ordinary shares to continue its Phase 1 clinical trials for its Chimeric Antigen Receptor T-cell therapy, HG-CT-1, aimed at treating relapsed/refractory acute myeloid leukemia in adults. This funding, obtained at a premium to the market price, reflects investor confidence in the company’s progress and potential, with the new shares and accompanying warrants expected to be admitted to trading on the LSE by early September 2025.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company based in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 39,167
Technical Sentiment Signal: Sell
Current Market Cap: £8.13M
See more data about HEMO stock on TipRanks’ Stock Analysis page.